Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
J. Neurochem. (2010) 114, 784–794. Positron emission tomography (PET) radioligands that bind selectively to β‐amyloid plaques (Aβ) are promising imaging tools aimed at supporting the diagnosis of Alzheimer’s disease and the evaluation of new drugs aiming to modify amyloid plaque load. For extended clinical use, there is a particular need for PET tracers labeled with fluorine‐18, a radionuclide with 110 min half‐life allowing for central synthesis followed by wide distribution. The development of fluorinated radioligands is, however, challenging because of the lipophilic nature of aromatic fluorine, rendering fluorinated ligands more prone to have high non‐specific white matter binding. We have here developed the new benzofuran‐derived radioligand containing fluorine, AZD4694 that shows high affinity for β‐amyloid fibrils in vitro (Kd = 2.3 ± 0.3 nM). In cortical sections from human Alzheimer’s disease brain [3 H]AZD4694 selectively labeled β‐amyloid deposits in gray matter, whereas there was a lower level of non‐displaceable binding in plaque devoid white matter. Administration of unlabeled AZD4694 to rat showed that it has a pharmacokinetic profile consistent with good PET radioligands, i.e., it quickly entered and rapidly cleared from normal rat brain tissue. Ex vivo binding data in aged Tg2576 mice after intravenous administration of [3 H]AZD4694 showed selective binding to β‐amyloid deposits in a reversible manner. In Tg2576 mice, plaque bound [3 H]AZD4694 could still be detected 80 min after i.v. administration. Taken together, the preclinical profile of AZD4694 suggests that fluorine‐18 labeled AZD4694 may have potential for PET‐visualization of cerebral β‐amyloid deposits in the living human brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“The solution was incubated with slow magnetic stirring at 22 C for 4 days before being frozen in aliquots at )80 C (Yang et al. 2005).”
MethodSperling, R. A., LaViolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., Marshall, G., Hyman, B. T., Selkoe, D. J., Hedden, T., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.003 · Cited by 1,027
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“[11C]PIB has been evaluated in over 40 different centers and in 3000 participants around the worlds, including postmortem analysis of AD patients (Ikonomovic et al. 2008; Klunk and Mathis 2008).”
BackgroundPrice, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90006-6 · Cited by 818
Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · cited 1×
“The presence ofAb plaques,with veryminor cognitive dysfunction may thus indicate a prodromal stage of AD where emerging disease-modifying therapieswould have a greater possibility to achieve a preventive and more durable beneficial effect (Pike et al. 2007 Morris et al. 2009).”
BackgroundRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Necula, M., Kayed, R., Milton, S., & Glabe, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608207200 · Cited by 680 · cited 2×
“and incubated with slow magnetic stirring at 22 C for 6 days before being frozen in aliquots at )80 C (Necula et al. 2007).”
MethodInfluentialNeuropathology of Cognitively Normal Elderly
Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661
Cited by
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603
Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias
Villemagne, V. L., Ong, K., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G., O'Keefe, G., Ackerman, U., Tochon-Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 372
Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329
Clinical amyloid imaging in Alzheimer's disease
Herholz, K., & Ebmeier, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70123-5 · Cited by 240
Shimada, H., Hirano, S., Sinotoh, H., Ota, T., Tanaka, N., Sato, K., Yamada, M., Fukushi, K., Irie, T., Zhang, M. R., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4338 · Cited by 40
“The recently developed in vivo tracking of amyloid (Klunk et al., 2004; Rowe et al., 2008; Choi et al., 2009; Juréus et al., 2010; Vandenberghe et al., 2010) and tau pathologies (Chien et al., 2013; Maruyama et al., 2013; Okamura et al., 2013) using positron emission tomography (PET) is expected to…”
Background
Metadata
- Authors
- Juréus, A., Swahn, B., Sandell, J., Jeppsson, F., Johnson, A. E., Johnström, P., Neelissen, J. A. M., Sunnemark, D., Farde, L., & Svensson, S. P. S.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2010-07-06
- Volume
- 114
- Issue
- 3
- Pages
- 784-794
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1959197363
- Cited by
- 141
- References
- 14
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand. https://app.cochat.ai/papers/10.1111/j.1471-4159.2010.06812.x
- The paper
- Juréus, A., Swahn, B., Sandell, J., Jeppsson, F., Johnson, A. E., Johnström, P., Neelissen, J. A. M., Sunnemark, D., Farde, L., & Svensson, S. P. S. (2010). Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2010.06812.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.